• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Devgen NV - Product Pipeline Review - Q4 2010 - Product Image

Devgen NV - Product Pipeline Review - Q4 2010

  • ID: 1446779
  • November 2010
  • 38 pages
  • Global Markets Direct

Devgen NV – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Devgen NV - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Devgen NV - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Devgen NV human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product READ MORE >



List of Tables
List of Figures
Devgen NV Snapshot
Devgen NV Overview
Key Information
Key Facts
Devgen NV – Research and Development Overview
Key Therapeutic Areas
Devgen NV – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Devgen NV – Pipeline Products Glance
Devgen NV–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Devgen NV – Drug Profiles
CDE5110
Product Description
Mechanism of Action
R&D Progress
CDE5498
Product Description
Mechanism of Action
R&D Progress
CDE6960
Product Description
Mechanism of Action
R&D Progress
Drug for diabetes
Product Description
Mechanism of Action
R&D Progress
Drug For Obesity
Product Description
Mechanism of Action
R&D Progress
CDE6963
Product Description
Mechanism of Action
R&D Progress
Drug for auto-immune diseases
Product Description
Mechanism of Action
R&D Progress
Inflammation drug
Product Description
Mechanism of Action
R&D Progress
Devgen NV – Pipeline Analysis
Devgen NV – Pipeline Products by Therapeutic Class
Devgen NV Pipeline Products By Target
Devgen NV – Pipeline Products by Molecule Type
Devgen NV - Dormant Projects
Devgen NV – Company Statement
Devgen NV – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
Devgen NV, Deals Volume Summary, 2004 to YTD 2010
Devgen NV, Deals Summary By Region, 2004 to YTD 2010
Devgen NV, Deals Summary, 2004 to YTD 2010
Devgen NV Detailed Deal Summary
Asset Purchase
Devgen Seeds Acquires Assets From Monsanto
Equity Offering
Devgen Completes Private Placement Of $25 Million
Devgen Completes IPO For $43 Million
Monsanto Partners With Devgen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS